Literature DB >> 30685840

The Stratified Population Screening of Hereditary Hemorrhagic Telangiectasia.

Tamás Major1,2, Réka Gindele3, Zsuzsanna Szabó3, Zsuzsanna Kis4, László Bora5, Natália Jóni6, Péter Bárdossy7, Tamás Rácz8, Zsuzsanna Bereczky3.   

Abstract

Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant multisystemic vascular disease with a wordwide prevalence of 1:5000-1:10000. We introduce our algorithm for the stratified population screening of HHT. Probands are selected from the consecutive hospital database review for HHT (I7800) and recurrent epistaxis (R0400) and the review of patient records referred by family practicioners. A proportion of probands might be de novo diagnosed with HHT in the 10-year study period. The checkup of probands consists of physical examination, arteriovenous malformation exploration and and genetic testing (ACVRL1 and ENG sequence analysis). The family screening of HHT consists of physical examination and screening for the family-specific mutation of each at-risk individual, and furthermore, arteriovenous malformation exploration in individuals with suspected/definite HHT and/or carrying the mutation. Twenty-five definite HHT patients were explored: 7 of them by the I7800 review, 1 by the R0400 review, 3 were de novo diagnosed, and the remaining 14 were explored by the systematic family screening. Considering the 20 patients alive at the end of the study period and the unavailable 5 potential HHT patients and 12 at-risk family members, the HHT prevalence is estimated to be 1:6090-1:11267 in our study area, implying our algorithm's effectivity in the stratified population screening of HHT.

Entities:  

Keywords:  ACVRL1; ENG; Founder effect; Hereditary hemorrhagic telangiectasia; Prevalence; Stratified screening

Mesh:

Substances:

Year:  2019        PMID: 30685840     DOI: 10.1007/s12253-019-00602-7

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  6 in total

1.  Mutation analysis in Norwegian families with hereditary hemorrhagic telangiectasia: founder mutations in ACVRL1.

Authors:  K Heimdal; B Dalhus; O K Rødningen; M Kroken; K Eiklid; S Dheyauldeen; T Røysland; R Andersen; M A Kulseth
Journal:  Clin Genet       Date:  2015-06-05       Impact factor: 4.438

2.  Mutations in endoglin and in activin receptor-like kinase 1 among Danish patients with hereditary haemorrhagic telangiectasia.

Authors:  K Brusgaard; A D Kjeldsen; L Poulsen; H Moss; P Vase; K Rasmussen; T A Kruse; M Hørder
Journal:  Clin Genet       Date:  2004-12       Impact factor: 4.438

Review 3.  Hereditary haemorrhagic telangiectasia.

Authors:  A A Sharathkumar; A Shapiro
Journal:  Haemophilia       Date:  2008-11       Impact factor: 4.287

4.  Hereditary hemorrhagic telangiectasia: evidence for regional founder effects of ACVRL1 mutations in French and Italian patients.

Authors:  Gaetan Lesca; Emmanuelle Genin; Claire Blachier; Carla Olivieri; Florence Coulet; Guy Brunet; Sophie Dupuis-Girod; Elisabetta Buscarini; Florent Soubrier; Alain Calender; Cesare Danesino; Sophie Giraud; Henri Plauchu
Journal:  Eur J Hum Genet       Date:  2008-02-20       Impact factor: 4.246

5.  Genotype-phenotype correlation in hereditary hemorrhagic telangiectasia: mutations and manifestations.

Authors:  Pinar Bayrak-Toydemir; Jamie McDonald; Boaz Markewitz; Susan Lewin; Franklin Miller; Lan-Szu Chou; Friederike Gedge; Wei Tang; Hillary Coon; Rong Mao
Journal:  Am J Med Genet A       Date:  2006-03-01       Impact factor: 2.802

6.  International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia.

Authors:  M E Faughnan; V A Palda; G Garcia-Tsao; U W Geisthoff; J McDonald; D D Proctor; J Spears; D H Brown; E Buscarini; M S Chesnutt; V Cottin; A Ganguly; J R Gossage; A E Guttmacher; R H Hyland; S J Kennedy; J Korzenik; J J Mager; A P Ozanne; J F Piccirillo; D Picus; H Plauchu; M E M Porteous; R E Pyeritz; D A Ross; C Sabba; K Swanson; P Terry; M C Wallace; C J J Westermann; R I White; L H Young; R Zarrabeitia
Journal:  J Med Genet       Date:  2009-06-23       Impact factor: 6.318

  6 in total
  2 in total

1.  Pitfalls of delaying the diagnosis of hereditary haemorrhagic telangiectasia.

Authors:  Tamás Major; Csaba Csobay-Novák; Réka Gindele; Zsuzsanna Szabó; László Bora; Natália Jóni; Tamás Rácz; Tamás Karosi; Zsuzsanna Bereczky
Journal:  J Int Med Res       Date:  2019-09-11       Impact factor: 1.671

2.  Resolving Differential Diagnostic Problems in von Willebrand Disease, in Fibrinogen Disorders, in Prekallikrein Deficiency and in Hereditary Hemorrhagic Telangiectasia by Next-Generation Sequencing.

Authors:  Réka Gindele; Adrienne Kerényi; Judit Kállai; György Pfliegler; Ágota Schlammadinger; István Szegedi; Tamás Major; Zsuzsanna Szabó; Zsuzsa Bagoly; Csongor Kiss; János Kappelmayer; Zsuzsanna Bereczky
Journal:  Life (Basel)       Date:  2021-03-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.